Price Chart

Price Chart

Key Stats

Net Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.59% 0.13% 5.539M 2041.67
Weighted Average Dividend Yield Turnover Ratio (Generic) 1 Year Fund Level Flows Max Drawdown (Since Inception)
1.68% 70.00% 1.724M

Basic Info

Investment Strategy
The Fund seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. It invests at least 80% of its net assets in securities that comprise the Index which is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business.
General
Security Type Exchange-Traded Fund
Equity Style Large Cap Growth
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Global Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro World Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Global Health/Biotechnology Funds
Fund Owner Firm Name Amplify ETFs
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Performance Versus Peer Group

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Peer Group Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Peer Group (NAV)
--
--
--
--
--
--
--
--

Annual Total Returns Versus Peers

Loading chart...
Name
2019
2020
2021
2022
2023
2024
2025
YTD
--
--
--
--
--
--
13.66%
9.95%
27.67%
15.90%
21.82%
-18.14%
23.79%
18.67%
21.09%
13.19%
--
65.01%
-0.31%
-33.72%
-2.94%
2.68%
23.92%
22.99%
19.74%
12.96%
-3.59%
-4.83%
2.55%
5.89%
24.25%
31.74%
18.65%
25.66%
1.54%
-10.83%
3.71%
1.10%
24.84%
20.68%
4.65%
11.31%
14.58%
-2.16%
-2.18%
9.62%
27.97%
25.10%
As of August 27, 2026.

Asset Allocation

As of July 31, 2026.
Type % Net
Cash 0.70%
Stock 98.59%
Bond 0.52%
Convertible 0.00%
Preferred 0.00%
Other 0.19%
View Asset Allocation
Start Trial

Basic Info

Investment Strategy
The Fund seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. It invests at least 80% of its net assets in securities that comprise the Index which is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business.
General
Security Type Exchange-Traded Fund
Equity Style Large Cap Growth
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Global Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro World Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Global Health/Biotechnology Funds
Fund Owner Firm Name Amplify ETFs
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Top Portfolio Holders